Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

Abstract

carcinoma (mRCC). The purpose of this study was to assess the budget impact of including sunitinib as first-line therapy (1L) option for mRCC patients, within a 3 year time horizon from the payer perspective in Argentina. METHODS: An excelbased budget impact model (BIM) was adapted to the context of Argentina to determine the incremental cost of introducing sunitinib in the 1L for patients with mRCC. The analysis was conducted with 2 comparators based on Argentina treatment pattern: pazopanib and sunitinib. Epidemiology data of mRCC was obtained from the literature. The drugs costs were obtained from ANMAT's National Drug Vademecum. The costs of drug administration and patient monitoring, and adverse events costs were estimated through a microcosting approach, based on published data and expert opinion, and were based on tariffs from healthcare institutions (social security and private sector) of Argentina. The market share of the different drugs was based on market studies and assumptions. The budget impact is reported in terms of annual budget impact, per-member per-year (PMPY) and per-patient per-year (PPPY). RESULTS: In Argentina assuming a population of 1 million people, patients eligible for 1L treatment were estimated at 27. The net budget impact estimated for the introduction of sunitinib was -$9,250.08 each year. The cumulative net budget impact was -$27,750.24, representing an impact of -1.94% compared to a scenario without sunitinib. The incremental cost PMPY was -$0.01, and the incremental cost PPPY was -$338.48. In one-way sensitivity analysis the price of sunitinib was the only one that showed a significant influence on the results. CONCLUSIONS: Our results suggest that the inclusion of sunitinib as a therapeutic option in patients with mRCC could generate budgetary savings compared to treatment with pazopanib.OBJECTIVES: Acute lymphoblastic leukemia (ALL) in adults is an acute and frequently fatal rare disease associated with high rates of relapse and substantial humanistic and economic burden. The primary objective of this study was to evaluate the budget impact (BI) of the implementation of inotuzumab ozogamicin as a treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). METHODS: A BI model was built in Excel to evaluate the economic impact of inotuzumab for the treatment of ALL in Bulgaria. For the base case analysis, the model was developed and populated with epidemiologic local data and compares the total budgetary costs (direct costs only) of a scenario with inotuzumab versus a scenario without inotuzumab. Costs were calculated according to the Positive Drug List (PDL) as of March 2018. The base case time horizon in the model was 5 years. RESULTS: The BI analysis estimated that the inclusion of inotuzumab in the reimbursement list would bring a saving of -4 917 BGN in the first year of incorporation, reaching -14 750 BGN savings in year five. The cumulative impact over 5-year time horizon corresponds to a total saving of -49 168 BGN. The sensiti...